FDA Approves XTORO — Fonseca Biosciences, LLC

# FDA Approves Fonseca Biosciences' XTORO for Ear Infections The FDA has approved Fonseca Biosciences' XTORO (finafloxacin), an otic fluoroquinolone antibiotic for auricular administration, establishing the company's entry into the specialized market for topical ear infection treatments. The approval of this novel formulation positions Fonseca to capture share in the underserved otic antibiotics segment, where treatment options have historically been limited.